triple agonist glp-1 A peptide of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss π A triple-action once-weekly injection
Description
One study found that GLP-1 use was associated with a reduction in alcohol cravings
But used wisely, with resistance training, protein optimisation, and patient selection, they may represent the most significant advance in cardiometabolic medicine since statins
doi: 10.1016/j.oret.2024.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar] 10.Hathaway JT, Shah MP, Hathaway DB, et al
What to discuss with your provider Be direct about your goals
Osmotic pump drug delivery systems-a comprehensive review
Once discontinued, many patients experience appetite rebound, making sustained weight loss challenging
